What treatment options are available for a patient experiencing depression, anxiety, and panic attacks, with a history of recent job loss, strained family relationships, excessive napping, and overthinking?

Treatment for Depression, Anxiety, and Panic Attacks

Start with an SSRI (sertraline 25-50 mg daily or escitalopram 5-10 mg daily) combined with cognitive behavioral therapy (CBT), as this combination provides superior outcomes compared to either treatment alone for patients with depression, anxiety, and panic attacks. 1, 2, 3

Immediate Assessment Priorities

Before initiating treatment, you must:

• Rule out suicidal ideation or intent - if present, refer immediately for emergency psychiatric evaluation 4
• Screen for substance use (drugs, alcohol) that may be causing or worsening symptoms 4
• Assess for medical causes of anxiety including thyroid dysfunction, cardiac issues, or medication side effects 4
• Evaluate for bipolar disorder - excessive energy, decreased need for sleep, or racing thoughts would contraindicate standard antidepressants and require mood stabilizer first 4

First-Line Pharmacotherapy

Sertraline is the optimal first choice due to extensive evidence across multiple anxiety disorders, depression, and panic disorder, with lower risk of drug interactions and discontinuation symptoms compared to other SSRIs 1, 5:

• Start at 25-50 mg daily (lower dose minimizes initial anxiety/agitation that can occur with SSRIs) 1
• Increase by 25-50 mg every 1-2 weeks as tolerated 1
• Target therapeutic dose: 50-200 mg/day 1, 5
• Expected timeline: statistically significant improvement by week 2, clinically meaningful improvement by week 6, maximal benefit by week 12 1

Alternative first-line option - Escitalopram:

• Start 5-10 mg daily, increase by 5-10 mg every 1-2 weeks 1
• Target dose: 10-20 mg/day 1

Critical Medication Warnings

• Monitor closely for suicidal thinking, especially in first months and after dose changes - pooled risk is 1% vs 0.2% placebo, but this is a black box warning for all antidepressants 1, 6, 7
• Common side effects (emerge in first few weeks, typically resolve): nausea, headache, insomnia, sexual dysfunction, diarrhea, dizziness 1, 6
• Do not combine with MAOIs - must wait 2 weeks after stopping MAOI before starting SSRI 6
• Avoid abrupt discontinuation - taper gradually to prevent withdrawal symptoms (anxiety, irritability, electric shock sensations, dizziness) 6

Mandatory Psychotherapy Component

Individual CBT is essential and should be initiated concurrently with medication - the combination produces effect sizes approximately twice as large as medication alone 1, 8:

• Structure: 12-20 sessions over 3-5 months, each 60-90 minutes 1, 5
• Core CBT elements must include 1:
  • Psychoeducation about anxiety/depression symptoms and treatment
  • Cognitive restructuring to challenge negative thought patterns (addresses "overthinking")
  • Relaxation techniques (breathing exercises, progressive muscle relaxation)
  • Behavioral activation to counter excessive napping and withdrawal
  • Gradual exposure to anxiety-provoking situations when appropriate

Individual CBT is superior to group therapy for anxiety disorders with large effect sizes (Hedges g = 1.01) and better cost-effectiveness 1

Addressing Specific Symptoms

For excessive napping and low energy:

• Screen for anemia, thyroid dysfunction, sleep apnea 4
• Encourage regular cardiovascular exercise - provides moderate to large reduction in anxiety symptoms 1
• Implement behavioral activation strategies through CBT to establish regular sleep-wake schedule 4

For overthinking/rumination:

• CBT specifically targeting rumination patterns is essential 1
• Mindfulness-based techniques and thought reframing strategies 1
• Grounding techniques (noticing environmental details, sensory awareness) 1

For panic attacks:

• Interoceptive exposure techniques in CBT help desensitize to physical sensations 2
• Breathing retraining to prevent hyperventilation 1

Psychosocial Support

Address contextual stressors that are maintaining symptoms 4:

• Job loss: Provide resources for employment assistance, financial counseling
• Family conflict: Consider family therapy or family psychoeducation sessions - family dynamics significantly affect treatment response and relapse rates 4
• Social isolation: Encourage maintenance of peer relationships and social activities 4

Monitor caregivers/family members - up to one-third of caregivers of patients with depression/anxiety are at risk for clinical depression themselves and may need referral 4

Treatment Monitoring and Adjustment

Follow-up schedule 4:

• Weekly for first month to monitor suicidal ideation and medication tolerability
• Monthly thereafter until symptoms stabilize
• Use standardized scales (GAD-7 for anxiety, PHQ-9 for depression) at each visit 4

If inadequate response after 8-12 weeks at therapeutic dose 4, 1:

1. Verify medication compliance and address barriers
2. Ensure CBT is being delivered with fidelity
3. Switch to different SSRI (e.g., sertraline to escitalopram or vice versa) 1
4. Consider SNRI (venlafaxine XR 75-225 mg/day or duloxetine 60-120 mg/day) as second-line 1, 5

Medications to Avoid

Do NOT prescribe benzodiazepines for chronic treatment - they carry high risk of dependence, tolerance, cognitive impairment, and may worsen anxiety long-term 4, 1, 5. Reserve only for short-term crisis management if absolutely necessary 1

Do NOT prescribe bupropion - it lacks efficacy for anxiety disorders and may worsen anxiety, agitation, and panic symptoms 5

Treatment Duration

• Continue medication for minimum 6-12 months after remission to prevent relapse 9
• Taper gradually when discontinuing - use slower taper for shorter half-life SSRIs like sertraline (reduce by 25 mg every 1-2 weeks) 1, 6
• Reevaluate treatment preferences after depression improves, as depression is associated with preferences to limit treatment that may change with successful treatment 4

When to Refer to Psychiatry

Immediate referral needed for 4:

• Active suicidal ideation with plan or intent
• Psychotic symptoms
• Suspected bipolar disorder
• No response to two adequate trials of SSRIs plus CBT
• Severe symptoms requiring intensive treatment